# Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Study · id `cardio:ct-nct07033585` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07033585](<https://clinicaltrials.gov/study/NCT07033585>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07033585

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07033585. Randomized; quadruple masking; primary purpose health services research. Start 2026-06-15 (actual); primary completion 2026-10-18 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose health services research
- Phase: Phase 2/3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07033585, source copy `cardio:ctgov-nct07033585-2026-08-27`, retrieved 2026-10-26)
- Started: 2026-06-15 (actual) (ClinicalTrials.gov record NCT07033585, source copy `cardio:ctgov-nct07033585-2026-08-27`, retrieved 2026-10-26)
- Primary completion: 2026-10-18 (anticipated) (ClinicalTrials.gov record NCT07033585, source copy `cardio:ctgov-nct07033585-2026-08-27`, retrieved 2026-10-26)
- Completion: 2026-11-28 (anticipated) (ClinicalTrials.gov record NCT07033585, source copy `cardio:ctgov-nct07033585-2026-08-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07033585, source copy `cardio:ctgov-nct07033585-2026-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07033585-2026-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
- Acronym: GD-T2D
- Condition: Type 2 Diabetes
- Intervention (Drug): Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- Intervention (Drug): China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
- Lead sponsor class: INDUSTRY
- Collaborator: UnitedHealthcare
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 8dfda6747df4bf8ed604bc641169ed20b69d80b022b419298dbe8a0e73e038e7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
